Olanzapine

Introduction Overview

Generic Name

olanzapine

Brand Name

Zyprexa, Zyprexa Zydis, Zyprexa Intramuscular, Zyprexa Relprevv

Dosage Form

oral tablets, orally disintegrating tablets, intramuscular injection, long-acting intramuscular injection (Zyprexa Relprevv)

Drug Class

Atypical antipsychotics

Pharmacokinetics

Absorption:
Olanzapine is well absorbed after oral administration, with peak plasma concentrations typically reached within 5 to 8 hours. The bioavailability of olanzapine is not significantly affected by food intake, allowing dosing with or without meals. After intramuscular injection, olanzapine exhibits rapid absorption, with peak concentrations occurring within 15 to 45 minutes, which makes it effective for acute agitation. The orally disintegrating tablets rapidly disintegrate in saliva, facilitating convenient uptake without need for water. First-pass metabolism influences the oral bioavailability, but specific absolute bioavailability values range approximately 60%. Overall, olanzapine’s absorption is reliable and consistent under varied clinical conditions.

Distribution:
Olanzapine is extensively distributed throughout the body. It is approximately 93% bound to plasma proteins, predominantly albumin and alpha-1 acid glycoprotein, which can influence free drug levels especially in states altering protein binding. The steady-state volume of distribution ranges from 9 to 17 L/kg, indicating extensive extravascular tissue distribution including the brain. Olanzapine readily crosses the blood-brain barrier to exert its central nervous system effects. Distribution is not significantly altered by gender or age; however, tissue binding and hepatic function can modulate levels. The drug is moderately lipophilic, which supports its broad tissue penetration.

Metabolism:
Olanzapine undergoes extensive hepatic metabolism primarily via direct glucuronidation and cytochrome P450-mediated oxidation. The major oxidative pathways involve CYP1A2, and to a lesser extent CYP2D6 and CYP3A4. The principal metabolites include 10-N-glucuronide (inactive) and 4'-N-desmethyl olanzapine (pharmacologically active but much less potent than parent drug). Smoking induces CYP1A2 and can lead to increased clearance and decreased plasma olanzapine concentrations. Liver impairment can reduce metabolic clearance. Olanzapine’s metabolism is subject to interactions with CYP modulators affecting drug exposure.

Elimination:
The elimination half-life of olanzapine is approximately 21 to 54 hours, varying according to the patient’s age, smoking status, and metabolic capacity. The drug is eliminated primarily via hepatic metabolism followed by renal and fecal excretion of metabolites. Less than 10% of the parent drug is excreted unchanged in the urine. Clearance rates are reduced in elderly and those with hepatic impairment, prolonging half-life. Steady state is typically achieved within 7 to 14 days of consistent dosing, supporting once-daily administration. The long half-life and metabolism make olanzapine amenable to both oral and intramuscular formulations with sustained therapeutic levels.

Dosage Forms

Available Dosage Forms:
- Oral Tablets: olanzapine 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg tablets (non-scored)
- Orally Disintegrating Tablets (Zyprexa Zydis): 5 mg, 10 mg, 15 mg, and 20 mg doses; tablets disintegrate rapidly in the mouth without need for water
- Intramuscular Injection (Zyprexa Intramuscular): 10 mg vials; short-acting formulation for acute agitation
- Long-Acting Intramuscular Injection (Zyprexa Relprevv): extended-release injectable used for maintenance treatment (not detailed in raw data)

Dosages for Adults and Adolescents:
- Schizophrenia (Adults and Adolescents 13+): Initial oral dose typically 5 mg to 10 mg once daily
- Bipolar I Disorder (Adults): Initial oral dose 10 mg to 15 mg once daily
- Bipolar I Disorder Depressive Episodes in Children 10+: used in combination with fluoxetine
- Intramuscular injection for acute agitation: usual dose 10 mg single injection; can administer 5 mg or 7.5 mg if appropriate; maximum of 3 doses spaced 2 to 4 hours apart
- Orally disintegrating tablets follow same dosing as oral tablets but provide ease of administration

Specific Patient Populations:
- Adolescents (13 years and older) indicated for schizophrenia and bipolar I disorder
- Pediatric use for depressive episodes only when combined with fluoxetine (from age 10)
- Not approved for children under 13 for schizophrenia or bipolar I disorder
- Dosing adjustments may be needed in hepatic impairment or elderly due to altered metabolism
- Smoking status influences dosing considerations; smokers may require higher doses
- Patients with diabetes or metabolic disorders require close monitoring and possible dose adaptation
- Intramuscular formulation reserved for acute agitation episodes in adults, contraindicated in elderly dementia-related psychosis

Mechanism Of Action

Olanzapine is a second-generation (atypical) antipsychotic whose therapeutic effects are primarily mediated through antagonism of multiple neurotransmitter receptors in the central nervous system. Its principal molecular targets include dopamine D2 receptors and serotonin 5-HT2A receptors, among others. By blocking D2 receptors, olanzapine modulates the dopaminergic pathways implicated in psychosis, thereby reducing positive symptoms such as hallucinations and delusions observed in schizophrenia.

Additionally, its high affinity antagonism of 5-HT2A receptors contributes to the amelioration of negative symptoms and cognitive deficits, distinguishing it from first-generation antipsychotics which are primarily dopaminergic antagonists. Olanzapine also exhibits antagonistic effects at muscarinic, histaminergic (H1), and alpha-1 adrenergic receptors, which contribute both to its efficacy and side effect profile including sedation, orthostatic hypotension, and anticholinergic adverse effects.

At the cellular level, olanzapine's blockade of dopamine and serotonin receptors leads to alterations in intracellular signaling pathways and modulation of neurotransmitter release, which ultimately regulates neuronal excitability and synaptic plasticity. This multi-receptor antagonism helps balance excitatory and inhibitory neurotransmission implicated in mood and psychotic disorders.

Comparatively, olanzapine's receptor binding profile differs from other atypical antipsychotics by its relatively higher affinity for histamine H1 and muscarinic receptors, explaining its pronounced sedative and metabolic side effects. Clinical studies have shown olanzapine’s efficacy across a broad range of symptoms in schizophrenia and bipolar disorder, attributed to this multifaceted receptor interaction. Moreover, combination therapy with fluoxetine enhances antidepressant effects through complementary serotonergic modulation, further broadening its utility in treatment-resistant depression.

Pharmacological Actions

Antagonism of dopamine D2 receptors leading to reduction of positive psychotic symptoms
Serotonin 5-HT2A receptor antagonism improving negative symptoms and cognitive function
Blockade of muscarinic acetylcholine receptors resulting in anticholinergic effects
Histamine H1 receptor antagonism causing sedation and weight gain
Alpha-1 adrenergic receptor antagonism contributing to orthostatic hypotension
Regulation of neurotransmitter release modulating dopamine and serotonin pathways
Modulation of intracellular signaling cascades affecting neuronal activity
Exhibits mood-stabilizing properties useful in bipolar I disorder
Synergistic effects when combined with fluoxetine for depressive episodes
Reduction of agitation via rapid CNS receptor blockade in intramuscular form
Impact on metabolic pathways leading to alterations in glucose and lipid homeostasis
Minimal extrapyramidal side effects compared to typical antipsychotics
Neuroprotective potential through serotonin-dopamine balance
Utility in treatment-resistant depression through multi-receptor mechanisms

Therapeutic Or Clinical Uses

Treatment of schizophrenia in adults and adolescents aged 13 years and older
Management of acute manic or mixed episodes in bipolar I disorder as monotherapy
Adjunctive therapy with lithium or valproate in bipolar I disorder manic episodes
Combination therapy with fluoxetine for depressive episodes associated with bipolar I disorder in patients aged 10 and older
Treatment-resistant depression in combination with fluoxetine (Symbyax)
Short-term intramuscular injection to manage acute agitation in schizophrenia and bipolar I mania in adults
Reduction of psychotic symptoms such as hallucinations, delusions, and disorganized thinking
Control of mood swings and mood stabilization in bipolar disorder
Off-label use considerations in other psychotic disorders guided by clinical judgment
Improvement in negative symptoms and cognitive dysfunction associated with schizophrenia
Management of agitation when oral administration is not feasible
Safety profile suitable for chronic maintenance therapy under monitoring
Reduction in the risk of relapse of psychotic or manic episodes
Treatment of mixed affective episodes in bipolar disorder
Supportive care in depression with psychotic features through serotonergic enhancement

Side Or Adverse Effects

Postural hypotension causing dizziness or fainting when standing up
Constipation commonly observed during therapy
Significant weight gain and increased appetite leading to metabolic concerns
Drowsiness and sedation affecting daytime functioning
Dizziness and related risks of falls, especially in elderly patients
Tremor and extrapyramidal symptoms although less frequent than typical antipsychotics
Dry mouth and anticholinergic effects
Headache and general malaise
Abdominal pain and gastrointestinal discomfort
Personality disorder or alterations in behavior reported
Restlessness or akathisia in some patients
Increased salivation and speech disorders
Forgetfulness or cognitive dulling
Pins and needles sensations (paresthesia) in the limbs
Elevated prolactin levels particularly in adolescents
Increased liver enzyme levels indicating hepatic stress
Neuroleptic malignant syndrome (NMS), a rare but potentially fatal condition
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), serious hypersensitivity reaction
Tardive dyskinesia with involuntary, persistent movements often of face and tongue
Hyperglycemia potentially leading to ketoacidosis and diabetic complications
Increased cholesterol and triglycerides contributing to cardiovascular risk
Seizures in patients with predisposition or history
Changes in blood cell counts, including leukopenia and neutropenia

Precautions

Use caution in elderly patients due to increased risk of stroke and death related to dementia-associated psychosis
Regular monitoring of blood glucose levels to detect hyperglycemia early
Monitoring of lipid profile due to risk of elevated cholesterol and triglycerides
Careful weight monitoring and encouragement of diet and exercise for metabolic control
Assess cardiovascular status including blood pressure to manage orthostatic hypotension risk
Screen for history of seizures or predisposition before initiating therapy
Patients with hepatic impairment may require dose adjustments due to altered metabolism
Avoid abrupt discontinuation; taper dosage over weeks to prevent withdrawal symptoms
Use caution when administered with other CNS depressants or sedatives
Monitor for signs of neuroleptic malignant syndrome and tardive dyskinesia
Avoid concomitant use with other drugs that lower blood pressure without medical supervision
Screen for glaucoma, prostate enlargement, and bowel obstruction prior to initiation
Educate patients on recognizing symptoms of hyperglycemia and adverse reactions
Assess mental health regularly for suicide risk especially when combined with fluoxetine
Precaution advised when used during pregnancy and lactation; weigh maternal benefits against fetal risks

Warnings

Boxed warning for increased risk of death in elderly patients with dementia-related psychosis
Increased risk of cerebrovascular adverse events including stroke and transient ischemic attacks in elderly demented patients
Potential for higher risk of suicidality when combined with fluoxetine in depression
Risk of severe hyperglycemia, including ketoacidosis, coma, and death
Risk of neuroleptic malignant syndrome, a life-threatening neurological emergency
Possibility of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), which requires immediate medical attention
Tardive dyskinesia may occur and can be irreversible; monitor for involuntary movements
Orthostatic hypotension leading to dizziness or falls especially on initiation and dose escalation
Difficulty swallowing may lead to aspiration pneumonia
Seizures may be precipitated or exacerbated
Potential alterations in blood cell counts requiring hematologic monitoring
Risk of heat intolerance and dehydration, especially in hot climates or during exercise
Use caution when performing tasks requiring alertness until drug effects are known
Not approved for pediatric use under 13 for schizophrenia or bipolar I disorder and under 10 for bipolar depression
Abrupt discontinuation can result in withdrawal symptoms and relapse

Contraindication

Known hypersensitivity to olanzapine or any component of the formulation
Use in elderly patients with dementia-related psychosis due to increased mortality risk
Concurrent use with other medications contraindicated because of interactions leading to serious adverse effects
Patients with narrow-angle glaucoma due to anticholinergic effects
Individuals with known severe hepatic impairment without specialist supervision
History of neuroleptic malignant syndrome induced by any antipsychotic
Known blood dyscrasias or severe leukopenia without rigorous monitoring
Use in children below approved age limits for specific indications (under 13 for schizophrenia/bipolar, under 10 for bipolar depression)
Acute intoxication with alcohol, CNS depressants, or other psychotropic agents precluding safe administration
Severe CNS depression or comatose states

Drug Interactions

Benzodiazepines (e.g., diazepam, lorazepam) may exacerbate orthostatic hypotension and sedation
Carbamazepine induces CYP1A2, potentially reducing olanzapine plasma levels and efficacy
Fluvoxamine inhibits CYP1A2, increasing olanzapine concentrations and risk of side effects
Fluoxetine may increase risk of suicidality and potentiates serotonergic effects when combined
Other CNS depressants and sedating antihistamines potentiate sedation and impair CNS function
Antihypertensive drugs may have additive hypotensive effects with olanzapine
Levodopa and dopamine agonists may have diminished therapeutic efficacy due to olanzapine’s dopamine antagonism
Anticholinergic drugs (e.g., benztropine) require careful use to avoid exacerbation of urinary retention or constipation
Alcohol increases sedation and risk of orthostatic hypotension and should be avoided
Opioids, muscle relaxants, and anxiolytics in combination may cause life-threatening respiratory depression
Drugs that inhibit or induce CYP enzymes modulating olanzapine metabolism affect plasma levels and clinical response
Use caution with medications that prolong QT interval as olanzapine may contribute to arrhythmia risk
Co-administration with valproate or lithium requires monitoring for additive CNS effects and toxicity
Significant interactions may require dose adjustment and close clinical monitoring
Pharmacodynamic and pharmacokinetic interactions necessitate informed prescribing and patient education

Preparations Of The Drug

Olanzapine 2.5 mg oral tablets containing olanzapine and inactive ingredients including carnauba wax, crospovidone, hydroxypropyl cellulose, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, titanium dioxide, and colorants
Olanzapine 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg oral tablets with similar inactive components
Olanzapine orally disintegrating tablets (Zyprexa Zydis) in 5 mg, 10 mg, 15 mg, and 20 mg doses containing gelatin, mannitol, aspartame, sodium methyl paraben, and sodium propylparaben as excipients
Olanzapine intramuscular injection (Zyprexa Intramuscular) 10 mg vial containing lactose monohydrate, tartaric acid, hydrochloric acid, and sodium hydroxide as inactive agents
Long-acting injectable formulations (Zyprexa Relprevv) designed for extended release (specific components and dosing form details not specified in provided data)
Manufactured by Eli Lilly and Company for brand formulations; multiple generic manufacturers including Apotex Inc., Dr Reddys Labs Ltd, and Zydus Pharms produce generic versions
Storage instructions recommend room temperature (20°C to 25°C), dry environment, away from light and moisture
Formulations provide oral and parenteral options to accommodate varying clinical needs including acute agitation and maintenance therapy